CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The TumAdoR project focuses on developing humanized antibodies that target CD73, an enzyme linked to cancer progression. By neutralizing CD73, the project aims to enhance immune responses against tumors and prevent cancer relapse, ultimately leading to new cancer immunotherapy options.
Studies have demonstrated the importance of CD73 in the spread of cancer.
Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microenvironment, and contributing to tumor proliferation and dissemination.
Neutralizing its activity represents a highly potent and innovative therapy.Following on the recent success of mAbs targeting immune checkpoint (PD1, CTLA4), TumAdoR aims to discover, characterize an…
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Marseille
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Finland, Turku
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, NEURIED
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Switzerland, LAUSANNE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
